Doxorubicin (DX) is among the most widely used cytotoxic agents because it is active on different kinds of human tumours (Bonadonna et al., 1975; Davis & Davis, 1979) . One limitation in its use, however, is the emergence of drug-resistance in the tumours under treatment (Kaye & Merry, 1985) . The development of resistance to drugs is a common clinical problem in the treatment of various cancers but the mechanisms responsible for its appearance are still not fully understood. It is also unknown whether the resistance is a characteristic of a cell subpopulation of the original tumour or it is induced by the treatment itself.
Human malignant melanoma is unresponsive to chemotherapy because of the emergence of subpopulations of resistant cells (Gaukroger et al., 1982) . On the contrary, the mouse melanoma B16 is sensitive to DX treatment (Goldin et al., 1981) . In order to study the mechanisms of drug resistance, we selected a cell line of B 16 melanoma with elevated levels of resistance to DX by continuous in vitro exposure to increasing concentrations of the drug. The DX-resistant and DX-sensitive cell lines were then characterized for different biological parameters in order to understand the possible basis of their different chemosensitivity. A calcium chelating agent and a calmodulin antagonist were used to circumvent drug resistance which was also challenged with some DX analogs, vincristine (VCR) and cisdiamminedichloroplatinum II (cis-DDP).
Materials and methods
Drugs DX, daunorubicin (DNR), 4'-epi-DX, 4'-deoxy-DX, 4'-deoxy-4'-iodio-DX, 4-demethoxy-DNR and cis-DDP were a gift from Farmitalia-Carlo Erba (Milan, Italy) . VCR was purchased from Eli-Lilly (Indianapolis, IN, USA). Verapamil was purchased as Isoptin by Knoll AG Liestal (Switzerland); trifluoperazine was obtained by Maggioni (Milan, Italy) . All drugs were dissolved in distilled water immediately before use.
Cell lines A B16 melanoma cell line (B16V) was obtained by mechanical disaggregation of a B16 melanoma tumour grown in syngeneic C57BL/6 mice. Cells were transferred in tissue culture in RPMI 1640 medium (Flow Laboratories, Irvine, Ayrshire, UK) containing 10% foetal calf serum (FCS) (Flow Laboratories), antibiotics and Fe(CN)6K3 0.03 mm as reported by Ellem & Kay (1983) ; cells were subcultured twice a week. After 5 in vitro passages, an aliquot of cells was grown in the presence of 5 ng ml -1 DX; drug concentration in the culture medium was then increased by 10 ng ml -1 every 1 or 2 weeks. This cell line was designated B16VDXR.
Cytotoxicity experiments Tumour cells (2 x 105ml-1) were seeded in complete culture medium in 6-well Costar tissue culture cluster (Costar, Cambridge, Mass, USA) and treated at cell seeding with different drug concentrations in replicate samples. After 72h, cells were harvested with trypsin-EDTA and counted in a Coulter Counter (ZBI, Electronics, Luton, UK); cell viability was determined by trypan blue dye exclusion. The resistance index (RI) was the ratio between the dose inhibiting the 50% (ID50) of the growth of B16VDXR and the ID50 of B16V cells. The ID50 was calculated from the curve of percent cell survival at different concentrations of the drug. In experiments performed in the presence of verapamil or trifluoperazine, these drugs were added to the culture medium at the same time of cell seeding whereas DX was added 24 h later; experiments were stopped 72 h after cell seeding. Doubling time and cloning efficiency The doubling time was obtained from the diagram of growth curves of B16V and B16VDXR cell lines by evaluating the time necessary for the population in logarithmic phase to double the cell number.
For the evaluation of cloning efficiency, 400 cells of B16V and B16VDXR were seeded in 5cm Petri dishes (Falcon, Becton Dickinson, CA, USA). After 7 and 10 days respectively, cells were fixed with methanol and stained with crystal-violet. Colonies of at least 20 cells were counted with an inverted microscope.
The mean cell diameter was obtained by counting 40 cells from a suspension obtained by trypsinization under a microscope with a calibrated eyepiece micrometer.
Melanin determination
Cells were harvested with trypsin-EDTA and collected in saline solution. Aliquots of cells were counted and protein concentration determined by the method of Lowry et al. (1951) . The remaining fraction used for melanin quantitation (Meyskens & Fuller, 1980) was resuspended in 1 ml of NaOH IN and DMSO 10% and kept at 37°C for 60min. Samples were read on a Beckman spectrophotometer at wavelength 470 nm.
Flow cytometric determination of DNA content Cells harvested with trypsin-EDTA were washed in PBS and resuspended in a solution of 0.1% sodium citrate containing 50 ug ml-1 propidium iodide (Calbiochem-Behring Corp., La Jolla, CA, USA), 50 U ml-1 RNAse A (Sigma, St Louis, MO, USA) and 0.05% triton X-100 (Calbiochem-Behring Corp.). Mouse thymocytes used as references of the diploid value, were processed in the same way. Flow cytometric measurements were performed with a microscope-based flow cytofluorimeter (Leitz, Wetzlar, West Germany), equipped with a 100WHg lamp as the source of excitation light. Excitation and emission wavelengths were selected by a BG 38 and a BG 12 excitation filters, a 580 nm chromatic beam splitter and a 610nm barrier filter. Fluorescence intensity, proportional to DNA content, was recorded by a multichannel analyzer (Spectrascope Modular 8000, Laben, Milan, Italy) and displayed as fluorescence histograms.
Intracellular distribution studies of DX. Intracellular distribution of DX was studied in cell monolayers grown on coverslips, incubated with the drug for 0.5, 24 or 48 h. At the end of the incubation, the coverslips were rinsed with PBS and mounted upside down on microscopic slides. The fluorescence intensity of anthracycline was analyzed subsequently in the nucleus and in the cytoplasm of each cell by performing spot measurements with a 2,pm diameter diaphragm. Measrurements were performed by a Leitz MPV 2 microscopephotometer, equipped with an automatic device for correction of lamp fluctuations (Freitas et al., 1981) , with a 95X oil immersion objective (NA 1.32). Excitation light was supplied by a xenon lamp XBO75W, and selected by excitation filters BG38(4mm), BG 12 (1.5mm) and chromatic beam splitter 495 nm. Emission light was collected by a barrier filter K 570. Quenching of nuclear fluorescence was considered not to affect the measurements significantly, since a linear relationship between fluorescence intensity and intracellular concentration has been reported (Speth et al., 1985) .
Results

Induction and level of DX resistance in B16 cells
The resistant variant cell line (B16VDXR) was obtained by continuous in vitro treatment of parental cells (B16V) with increasing concentrations of DX in the culture medium. As shown in Table I , the treatment induced increasing values of RI, without reaching a plateau up to a DX dose of To see whether by increasing DX concentrations all tumour cells were killed, the pattern of sensitivity of both B 16V and BI 6VDXR to increasing doses of DX was investigated. Figure 1 shows the results of this experiment. DX was 
Stability of resistance.
To assess the stability of drug resistance in our cell line, B16VDXR cells were subcultured in complete medium without DX for about 9 months (i.e. for 50 passages) and the sensitivity to DX was assayed at different passages (Figure 2) . No significant changes in the ID50 nor in the slope of the doseresponse curves were noted throughout the observation time. Thus, DX-resistance of the B16VDXR cell line seems to be a stable phenotype.
Determination of DNA content. The histograms of fluorescence intensity (proportional to the DNA content) of sensitive (a) and resistant (b) B16 melanoma cells, are shown in Figure 3 , together with the fluorescence distribution higher in sensitive than in the resistant cells. Other authors (Speth et al., 1985) reported that in these conditions quenching of fluorescence is minimal. Since quenching is a nuclear phenomenon it is possible that values of nuclear but not of cytoplasmic fluorescence are underestimated. Nevertheless, for long term treatments (48 h) the nuclear/cytoplasmic fluorescence ratio was lower around value of unity for both cell lines.
Multi-drug resistance. Pleiotropic drug-resistance has been reported for many different cell lines (Kaye & Merry, 1985) . We tested, therefore, whether B16VDXR cells were sensitive to the cytotoxic action of other anthracyclines and of anticancer drugs having (Ferrari et al., 1984; Kaplan et al., 1984; Holdener et al., 1985) , and 4'-deoxy-4'-iodio-DX, because it has been shown to be active on the DX-resistant P388 cell line (Facchinetti et al., 1984) . VCR, a typical DX cross-resistant drug (Wilkoff & Dulmadge, 1978) , and cis-DDP, a non DX crossresistant drug (Seeber et al., 1982) , were also tested. The results are shown in Figure 4 . 4'-Epi-DX ( Figure 4A ) appears to display complete crossresistance with DX.; 4'-deoxy-DX ( Figure 4B ) has a lower RI compared to DX (30 vs. 133), whereas 4'-deoxy-4'-iodio-DX ( Figure 4C) is not crossresistant, being cytotoxic to the same extent on both cell lines. As reported on several other DXresistant cell lines (Wilkoff & Dulmadge, 1978) , DNR showed cross-resistance with DX also on the B16VDXR line ( Figure 4D ), whereas its derivative 4-demethoxy-DNR ( Figure 4E ) was more active having a RI of 3. Cross-resistance of B16VDXR with VCR was also evident ( Figure 4F ), while cis-DDP ( Figure 4G ) resulted in a higher activity (2-fold) on B16VDXR than on B16V cells.
It is interesting to observe that in the sensitive line the dose-response curve of cells treated with DX and VCR shows a rapid fall at doses up to 40 and 8ngml-1 respectively, where a shoulder is the beginning of a plateau of activity which persists for drug concentrations -2 logarithmic units higher with 10-20% of surviving cells. On the same cell line the other DX-derivatives tested and also cis-DDP show a dose-dependent cytotoxicity which reaches, with different slopes, 100% of cell growth inhibition. For these drugs, therefore, no correlation can be found between RI and slope of activity. Circumvention of resistance by a calcium-chelating agent and a calmodulin-antagonist Experiments were then carried out with verapamil (a calcium-chelating agent) and trifluoperazine (a calmodulin-antagonist) in an attempt to circumvent drug resistance. Table V shows that the addition of 10 M of verapamil 24h before treatment and its presence during treatment induces in B16V cells a 5-fold increase of drug activity. In the B16VDXR cell line the same treatment enhances DX activity leading to a RI of 5 instead of 166 obtained in the absence of verapamil. Lower concentrations of the calcium-antagonist have a reduced effect, but significant at the highest doses of DX tested.
As with verapamil, treatment with trifluoperazine was started 24h before the addition of DX. The results of Table VI indicate that treatment with 8 gM trifluoperazine does not affect the activity of the drug on B16V cell line, while it enhances the activity of DX on B16VDXR cell line where the ID50 of the anthracycline is reduced 16-fold. The circumvention of DX-resistance is correlated with the concentration of trifluoperazine in the culture medium since with 1.6 gM trifluoperazine, the ID50 of DX is reduced only about 2-fold.
Discussion
Human malignant melanoma is a tumour resistant to different chemotherapeutic drugs including DX. It is unknown whether resistance is primary, that is intrinsic to malignant cells, or acquired upon drug treatment through mutation and/or cellular selection. Regardless of the type of mechanism, it has been observed that human melanoma cells manifest immediate or very early resistance to chemotherapy (Tanigawa et al., 1984) . On the contrary, transplanted murine B 16 melanoma is responsive to DX treatment (Goldin et al., 1981) . The aim of the present work was to induce a DX-resistant B 16 cell line and to characterize the mechanisms of drug-resistance in these cells.
Our experiments have shown that it is possible to obtain DX-resistant cells (Bi6VDXR) from an originally drug sensitive B16 line (B16V) by exposure to progressively increasing amounts of DX. Naturally DX-resistant cells, however, are likely to be present in the parental cell line since even high dose treatment of B16V was never able to kill 100% of cells, leaving 10-20% of tumour cells surviving to DX concentrations 100 times higher than the ID50 of the whole cell line. The same effect was found by treating the B16VDXR line, suggesting the possibility that cells could be obtained with a RI even higher than that already reached. In vitro selection of DX-resistant lines, however, might not be representative of the clinical situation. Although no direct comparison is available between in vitro and in vivo generated DX-resistant solid tumours, data obtained in vivo with murine leukaemias and MT mouse mammary carcinoma suggest that drug treatment eliminates drug-sensitive cells which compose the majority of the tumour leaving a pre-existing highly drugresistant cell subpopulation (Skipper et al., 1978; McMillan et al., 1985 (Yanovich & Preston, 1984) . A genetic basis for resistance has been reported in other drug resistant cell lines where the presence of double minutes and homogeneous staining regions was observed (Kaye & Merry, 1985) ; studies are in progress in B16VDXR cells to further characterize the increase in the content of DNA. Melanin content was variable during the time of cultivation of our sensitive line as already reported by other authors (De Pauw-Gillet et al., 1985) but it became a constant feature of B16VDXR cells. On the basis of the observation of a slight but stable increase of protein content, cell diameter and pigmentation and of a higher variability of these features in sensitive cells as compared with resistant cells, we can hypothesize that DX treatments selected cells already present in the parental cell line. Nevertheless, as the increase of pigmentation is considered an index of cell differentiation (Lotan & Lotan, 1980; Meyskens & Fuller, 1980) , it is also possible that continuous DX treatment induced this process in B16V cells, as previously suggested for pleiotropic drug resistant CHO cells (Biedler et al., 1975) .
The different cell shape can be due to some membrane alterations already observed in other drug resistant cells lines (Peterson et al., 1983) .
The difference in the intracellular distribution of DX may be partially responsible for resistance since our data indicate that at least in the first 24 h the nuclear/cytoplasmic ratio of DX content in Bl 6V cells was twice that of B16VDXR cells. This ratio was reduced and became similar in both cell lines after 48 h of culture in the presence of DX. Since DX uptake on other cell lines is known to be completed within 2h (Supino et al., 1977) these data suggest that after 24 and 48 h most of the drug has left the nucleus. These results agree with the observation of a disappearance of nuclear fluorescence in colon cancer cells cultivated for 1 day or longer in the presence of DX (Chauffert et al., 1984 (Hill et al., 1985) . Some anthracyclines showed a low RI like 4-demethoxy-DNR (RI=3) and 4'-deoxy-DX (RI=30) and these data too are in accordance with experimental and clinical trials (Ferrari et al., 1984; Kaplan et al., 1984; Hill et al., 1985) . 4'-Deoxy-4'-iodio-DX was cytotoxic on B16VDXR to the same extent as that on B16V. These findings, especially the lack of crossresistance between DX and 4'-deoxy-4'-iodio-DX, might be important for future clinical trials with these analogues. Since we discovered that resistance to DX is associated with a different intracellular distribution of the drug, it is possible that the same phenomenon is involved in the resistance or the sensitivity of B16VDXR cells to these anthracyclines.
B16VDXR cell line is resistant to VCR and sensitive to cis-DDP; The higher sensitivity of B16VDXR to cis-DDP as compared to the sensitive line suggests a collateral sensitivity which has been also found with in vivo treatment of these two B16 lines (Formelli et al., submitted for publication). This behaviour is similar to that of other DXresistant lines (Skovsgaard, 1978; Wilkoff & Dulmadge, 1978; Seeber et al., 1982) and the mechanisms of this phenomenon are at present unknown.
Many authors have discussed the possibility of circumventing DX-and VCR-resistance of different cell lines by pretreatment of cells with calciumantagonists (Tsuruo et al., 1983; Kessel & Wilberding, 1984; Kessel & Wilberding, 1985) or calmodulin-inhibitors (Tsuruo et al., 1982; Ganapathi & Grabowski, 1983) . Also, resistance of the B16 melanoma cell line could be reduced but not completely antagonized in the presence of subtoxic concentrations of verapamil or trifluoperazine. The activity of verapamil was shown to be dosedependent and more pronounced in B16VDXR than in B16V cell line. The activity of trifluoperazine was also dose-dependent but it was present only in B16VDXR cells where it induced a reduction of ID50 of only 16 times compared to the 33-fold reduction caused by verapamil. We have also observed that no alterations in DX cytotoxicity was induced on either cell line by increasing calcium-concentration up to subtoxic doses (8mM and 2mM) in the culture medium (data not shown). This may indicate that the effect of verapamil and trifluoperazine on DX cytotoxicity is dependent not only on alterations in calcium flux but also on other mechanisms.
In conclusion, the results reported in this paper indicate that this cell line can be a useful tool to investigate further the cellular alterations associated with drug resistance and to screen for drugs active on DX-resistant cells and for studies on the circumvention of DX-resistance.
